Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Herbert K Lyerly

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
Human Vaccines & Immunotherapeutics|December 13, 2023
CEA vaccinesAnchit Bhagat, Herbert K Lyerly, Michael A Morse, et al.
Molecular Cancer Therapeutics|April 22, 2010
X-linked inhibitor of apoptosis protein inhibits apoptosis in inflammatory breast cancer cells with acquired resistance to an ErbB1/2 tyrosine kinase inhibitorKatherine M Aird, Rami B Ghanayem, Sharon Peplinski, et al.
Oncology Letters|December 3, 2019
Predictive significance of T cell subset changes during <i>ex vivo</i> generation of adoptive cellular therapy products for the treatment of advanced non-small cell lung cancerLefu Huang, Guoliang Qiao, Michael A Morse, et al.
Molecular Cancer Therapeutics|January 19, 2008
Trastuzumab signaling in ErbB2-overexpressing inflammatory breast cancer correlates with X-linked inhibitor of apoptosis protein expressionKatherine M Aird, Xiuyun Ding, Aris Baras, et al.
Cancer Research|April 27, 2011
HER2 overexpression elicits a proinflammatory IL-6 autocrine signaling loop that is critical for tumorigenesisZachary C Hartman, Xiao-Yi Yang, Oliver Glass, et al.
Nature Communications|June 13, 2022
Gene expression signatures of individual ductal carcinoma in situ lesions identify processes and biomarkers associated with progression towards invasive ductal carcinomaClare A Rebbeck, Jian Xian, Susanne Bornelöv, et al.
Vaccine|October 18, 2011
Increasing vaccine potency through exosome antigen targetingZachary C Hartman, Junping Wei, Oliver K Glass, et al.
BMC Immunology|March 28, 2008
Precision and linearity targets for validation of an IFNgamma ELISPOT, cytokine flow cytometry, and tetramer assay using CMV peptidesHolden T Maecker, Jeffrey Hassler, Janice K Payne, et al.
Human Vaccines & Immunotherapeutics|February 8, 2024
Vaccines targeting <i>ESR1</i> activating mutations elicit anti-tumor immune responses and suppress estrogen signaling in therapy resistant ER+ breast cancerGabrielle P Dailey, Christopher A Rabiola, Gangjun Lei, et al.
Molecular Cancer Therapeutics|June 16, 2011
Truncated ErbB2 expressed in tumor cell nuclei contributes to acquired therapeutic resistance to ErbB2 kinase inhibitorsWenle Xia, Zuguo Liu, Rongrong Zong, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Human Vaccines & Immunotherapeutics|December 13, 2023
CEA vaccinesAnchit Bhagat, Herbert K Lyerly, Michael A Morse, et al.
Molecular Cancer Therapeutics|April 22, 2010
X-linked inhibitor of apoptosis protein inhibits apoptosis in inflammatory breast cancer cells with acquired resistance to an ErbB1/2 tyrosine kinase inhibitorKatherine M Aird, Rami B Ghanayem, Sharon Peplinski, et al.
Oncology Letters|December 3, 2019
Predictive significance of T cell subset changes during <i>ex vivo</i> generation of adoptive cellular therapy products for the treatment of advanced non-small cell lung cancerLefu Huang, Guoliang Qiao, Michael A Morse, et al.
Molecular Cancer Therapeutics|January 19, 2008
Trastuzumab signaling in ErbB2-overexpressing inflammatory breast cancer correlates with X-linked inhibitor of apoptosis protein expressionKatherine M Aird, Xiuyun Ding, Aris Baras, et al.
Cancer Research|April 27, 2011
HER2 overexpression elicits a proinflammatory IL-6 autocrine signaling loop that is critical for tumorigenesisZachary C Hartman, Xiao-Yi Yang, Oliver Glass, et al.
Nature Communications|June 13, 2022
Gene expression signatures of individual ductal carcinoma in situ lesions identify processes and biomarkers associated with progression towards invasive ductal carcinomaClare A Rebbeck, Jian Xian, Susanne Bornelöv, et al.
Vaccine|October 18, 2011
Increasing vaccine potency through exosome antigen targetingZachary C Hartman, Junping Wei, Oliver K Glass, et al.
BMC Immunology|March 28, 2008
Precision and linearity targets for validation of an IFNgamma ELISPOT, cytokine flow cytometry, and tetramer assay using CMV peptidesHolden T Maecker, Jeffrey Hassler, Janice K Payne, et al.
Human Vaccines & Immunotherapeutics|February 8, 2024
Vaccines targeting <i>ESR1</i> activating mutations elicit anti-tumor immune responses and suppress estrogen signaling in therapy resistant ER+ breast cancerGabrielle P Dailey, Christopher A Rabiola, Gangjun Lei, et al.
Molecular Cancer Therapeutics|June 16, 2011
Truncated ErbB2 expressed in tumor cell nuclei contributes to acquired therapeutic resistance to ErbB2 kinase inhibitorsWenle Xia, Zuguo Liu, Rongrong Zong, et al.
Pageof 2